Mosby's 2014 Nursing Drug Reference (252 page)

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

maraviroc (Rx)

(mah-rav′er-rock)

Selzentry

Func. class.:
Antiretroviral

Chem. class.:
Fusion inhibitor, CCR5-receptor antagonist

ACTION:

Interferes with entry into HIV-1 by inhibiting the fusion of the virus and the cell membrane

USES:

CCR5-tropic HIV in combination with other antiretroviral agents for treating experienced patients

CONTRAINDICATIONS:

Hypersensitivity, dialysis, renal impairment

Precautions:
Pregnancy (B), Asian patients, breastfeeding, renal/hepatic/cardiac disease, electrolyte imbalance, dehydration, immune reconstitution syndrome, infection, MI, orthostatic hypotension, children, geriatric patients, Graves’ disease, Guillain-Barré syndrome, polymyositis

 

Black Box Warning:

Hepatitis, fever, serious rash

DOSAGE AND ROUTES
Calculator
Those not taking any CYP3A inducers/inhibitors

• Adult/adolescent ≥16 yr:
PO
300 mg bid

Those taking CYP3A4 inhibitors with/without a CYP3A inducer

• Adult/adolescent ≥16 yr:
PO
150 mg bid

Those taking CYP3A4 inducers without a strong CYP3A inhibitor

• Adult/adolescent ≥16 yr:
PO
600 mg bid

Renal dose

• Adult:
PO
≤30 ml/min, reduce dose to 150 mg bid

Available forms:
Tabs 150, 300 mg

Administer:

• 
May give without regard to meals, with 8 oz water; swallow whole, do not crush, chew, break

SIDE EFFECTS

CV:
MI, cardiac ischemia, orthostatic hypotension

CNS:
Dizziness, depression,
viral meningitis,
disturbances in consciousness, peripheral neuropathy, paresthesia, dysesthesia, fever

EENT:
Gingival hyperplasia

GI:
Diarrhea, constipation, dyspepsia,
pseudomembranous colitis, hepatotoxicity

INTEG:
Rash, urticaria, pruritus, folliculitis

MS:
Joint pain, leg pain, muscle cramps

RESP:
Cough, upper respiratory tract infection, sinusitis, bronchitis, pneumonia,
bronchospasm, obstruction

SYST:
Herpes virus

PHARMACOKINETICS

Metabolized by P450 system; CYP3A metabolism; excreted 20% urine, 76% feces; protein binding 76%; terminal half-life 14-18 hr

INTERACTIONS

Increase:
maraviroc levels—CYP3A inhibitors (amiodarone, aprepitant, chloramphenicol, clarithromycin, conivaptan, cycloSPORINE, dalfopristin, danazol, diltiazem, erythromycin, estradiol, fluconazole, fluvoxaMINE, imatinib, isoniazid, itraconazole, ketoconazole, miconazole, nefazodone, niCARdipine, propoxyphene, RU-486, tamoxifen, telithromycin, troleandomycin, verapamil, voriconazole, zafirlukast); reduce dose

Decrease:
maraviroc levels—CYP3A4 inducers (efavirenz, aminoglutethimide, barbiturates, bexaroten, bosentan, carBAMazepine, dexamethasone, griseofulvin, modafinil, nafcillin, OXcarbazepine, phenytoin, fosphenytoin, rifabutin, rifampin, rifapentine, topiramate, tipranavir); increase dose

Drug/Herb

• 
Decreased maraviroc effect: St. John’s wort

Drug/Food

• 
High-fat meal decreases absorption 33%

NURSING CONSIDERATIONS
Assess:

• 
HIV:
CD
4
, T-cell count, plasma HIV RNA, CCR5-tropic HIV-1; assess for changes in symptoms, other infections during treatment

• 
Renal studies: serum creatinine

• 
Bowel pattern before, during treatment

• 
Allergies:
skin eruptions: rash, urticaria, itching; discontinue product

 

Black Box Warning:

Hepatitis:
dark urine; abdominal pain, vomiting; yellowing of skin, eyes; hepatomegaly; discontinue product; monitor liver function tests

Perform/provide:

• 
Storage at room temp

Evaluate:

• 
Therapeutic response: improvement in CD4, viral load, T-cell count

Teach patient/family:

• 
To take as prescribed; if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose; that product does not cure condition, should not be shared with others

• 
That product does not cure infection, just controls symptoms and does not prevent infecting others

 
To report sore throat, fever, fatigue
(may indicate superinfection);
yellow skin/eyes, abdominal pain, vomiting
(hepatitis);
itching, SOB
(allergic reaction)

• 
That product must be taken in equal intervals around the clock to maintain blood levels for duration of therapy

• 
To avoid all OTC products unless approved by prescriber

• 
To avoid driving, other hazardous activities until reaction is known; that dizziness may occur

• 
To make position changes slowly to prevent postural hypotension

• 
To notify prescriber if pregnancy is planned or suspected,
not to breastfeed

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

mebendazole (Rx)

(me-ben′da-zole)

Func. class.:
Anthelmintic

Chem. Class.:
Carbamate

ACTION:

Inhibits glucose uptake, degeneration of cytoplasmic microtubules in the cell; interferes with absorption, secretory function

USES:

Pinworms, roundworms, hookworms, whipworms, thread-worms, pork tapeworms, dwarf tapeworms, beef tapeworms, hydatid cyst

CONTRAINDICATIONS:

Hypersensitivity

Precautions:
Pregnancy (C) (1st trimester), breastfeeding, children <2yr, Crohn’s disease, hepatic disease, inflammatory bowel disease, ulcerative colitis

DOSAGE AND ROUTES
Calculator

• Adult and child >2 yr:
PO
100 mg as a single dose (pinworms) or bid ×3 days (whipworms, roundworms, or hookworms); course may be repeated in 3 wk if needed, max 200 mg/day

Available forms:
Chew tabs 100 mg

Administer:

• 
May be crushed, chewed, swallowed whole, mixed with food

• 
PO after meals to avoid GI symptoms

• 
Second course after 3 wk if needed; usually recommended

SIDE EFFECTS

CNS:
Dizziness, fever, headache,
seizures (rare)

GI:
Transient diarrhea, abdominal pain, nausea, vomiting, constipation, hepatitis

INTEG:
Rash

PHARMACOKINETICS
PO

Peak ½-7 hr; excreted in feces primarily (metabolites), small amount in urine (unchanged); highly bound to plasma proteins 95%

INTERACTIONS

Decrease:
mebendazole effect—carBAMazepine, hydantoins

Drug/Food

Increase:
absorption—high-fat meal

NURSING CONSIDERATIONS
Assess:

• 
Stools during entire treatment; specimens must be sent to lab while still warm, also 1-3 wk after treatment is completed

• 
For allergic reaction: rash (rare)

• 
For diarrhea during expulsion of worms; avoid self-contamination with patient’s feces

• 
For infection in other family members, since infection from person to person is common

• 
Blood studies: AST, ALT, alk phos, BUN, CBC during treatment

Perform/provide:

• 
Storage in tight container

Evaluate:

• 
Therapeutic response: expulsion of worms and 3 negative stool cultures after completion of treatment

Teach patient/family:

• 
Proper hygiene after BM, including hand-washing technique; tell patient to avoid putting fingers in mouth; clean fingernails

• 
That infected person should sleep alone; do not shake bed linen, change bed linen daily, wash in hot water, change and wash undergarments daily

• 
To clean toilet daily with disinfectant (green soap solution)

• 
The need for compliance with dosage schedule, duration of treatment

• 
To wear shoes, wash all fruits and vegetables well before eating; use commercial fruit/vegetable cleaner

• 
That all members of the family should be treated (pinworms)

• 
To report jaundice, liver pain

Other books

Dear Rose 2: Winter's Dare by Mechele Armstrong
The Dead Travel Fast by Nick Brown
His Lordship's Chaperone by Shirley Marks
Strange Blood by Lindsay Jayne Ashford
Friday Barnes 2 by R. A. Spratt
The Conquering Family by Costain, Thomas B.
Witches by Stern, Phil
The Red Line by R M Reef